LeMaitre Vascular, Inc. $LMAT Shares Sold by Squarepoint Ops LLC

Key Points

• Squarepoint Ops LLC cut its LeMaitre Vascular stake by 52.4% in the second quarter, selling 28,394 shares and retaining 25,768 shares worth approximately $2.47 million. Institutional investors collectively own 84.64% of the company.
• LeMaitre’s latest quarterly results missed analyst expectations, with EPS of $0.74 versus $0.81 expected and revenue of $70.38 million versus $71.47 million forecast. Revenue nevertheless increased 9.6% year over year.
• Analyst sentiment has weakened to a consensus “Hold” rating, although the average price target remains $110.60 compared with the stock’s reported $80.77 price. The company also maintains a quarterly dividend of $0.25, equivalent to a 1.2% annual yield.

Squarepoint Ops LLC lowered its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 52.4% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,768 shares of the medical instruments supplier's stock after selling 28,394 shares during the period. Squarepoint Ops LLC owned about 0.11% of LeMaitre Vascular worth $2,473,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Sound Income Strategies LLC lifted its stake in LeMaitre Vascular by 425.6% during the first quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier's stock valued at $25,000 after purchasing an additional 183 shares during the last quarter. Catalyst Capital Advisors LLC acquired a new position in LeMaitre Vascular in the first quarter worth approximately $32,000. Nykredit A S bought a new position in shares of LeMaitre Vascular in the second quarter valued at $82,000. Northwestern Mutual Wealth Management Co. bought a new position in shares of LeMaitre Vascular in the second quarter valued at $102,000. Finally, EverSource Wealth Advisors LLC lifted its position in shares of LeMaitre Vascular by 28.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,393 shares of the medical instruments supplier's stock valued at $152,000 after acquiring an additional 308 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors.

LeMaitre Vascular Price Performance

Shares of LMAT opened at $80.77 on Tuesday. The company has a market capitalization of $1.85 billion, a price-to-earnings ratio of 28.34, a P/E/G ratio of 2.33 and a beta of 0.50. LeMaitre Vascular, Inc. has a fifty-two week low of $78.27 and a fifty-two week high of $118.01. The company has a debt-to-equity ratio of 0.40, a current ratio of 16.31 and a quick ratio of 13.96. The business's 50-day moving average is $89.48 and its 200-day moving average is $98.71.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.81 by ($0.07). LeMaitre Vascular had a return on equity of 15.63% and a net margin of 25.02%.The company had revenue of $70.38 million during the quarter, compared to analysts' expectations of $71.47 million. During the same period last year, the company earned $0.60 earnings per share. LeMaitre Vascular's revenue for the quarter was up 9.6% compared to the same quarter last year. Equities research analysts expect that LeMaitre Vascular, Inc. will post 2.89 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, September 3rd. Shareholders of record on Thursday, August 20th were given a $0.25 dividend. The ex-dividend date was Thursday, August 20th. This represents a $1.00 dividend on an annualized basis and a yield of 1.2%. LeMaitre Vascular's dividend payout ratio is presently 35.09%.

Analyst Ratings Changes

Several research firms have recently weighed in on LMAT. Wall Street Zen lowered LeMaitre Vascular from a "buy" rating to a "hold" rating in a research note on Saturday, August 1st. Zacks Research downgraded LeMaitre Vascular from a "strong-buy" rating to a "hold" rating in a report on Monday, July 6th. Weiss Ratings lowered LeMaitre Vascular from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Friday, August 14th. Citigroup reiterated a "market outperform" rating on shares of LeMaitre Vascular in a research report on Tuesday, July 21st. Finally, Barrington Research downgraded LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Wednesday, August 5th. Three research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $110.60.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures and markets medical devices used primarily in the treatment of peripheral vascular disease. Its products are designed for vascular surgeons and other specialists performing procedures on arteries and veins outside the heart and brain.

The company's portfolio includes biologic and synthetic vascular grafts, thrombectomy catheters, angioplasty balloons, valvulotomes, vascular shunts, vessel-closure devices and other surgical instruments. LeMaitre also offers products used in vessel preparation, plaque removal and the repair or replacement of diseased blood vessels.

Founded in 1983 and headquartered in Burlington, Massachusetts, LeMaitre Vascular serves customers in the United States and international markets.

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.